ProductsDTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus) + DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b) + Inactivated Poliomyelitis Vaccine + Poliomyelitis Vaccine bivalent types 1 and 3 + Human Rotavirus, live attenuated + Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus) + DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b) + Inactivated Poliomyelitis Vaccine + Poliomyelitis Vaccine bivalent types 1 and 3 + Human Rotavirus, live attenuated + Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pertussis Immunisation

Conditions

Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type B Immunisation, Tetanus Immunisation, Rotavirus Immunisation, Pneumococcal Immunisation

Trial Timeline

Jun 28, 2020 → Nov 20, 2021

NCT ID

NCT04429295

About DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus) + DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b) + Inactivated Poliomyelitis Vaccine + Poliomyelitis Vaccine bivalent types 1 and 3 + Human Rotavirus, live attenuated + Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus) + DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b) + Inactivated Poliomyelitis Vaccine + Poliomyelitis Vaccine bivalent types 1 and 3 + Human Rotavirus, live attenuated + Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) is a phase 3 stage product being developed by Sanofi for Pertussis Immunisation. The current trial status is completed. This product is registered under clinical trial identifier NCT04429295. Target conditions include Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04429295	Phase 3	Completed	Jun 28, 2020	Nov 20, 2021	Pertussis Immunisation

Competing Products

16 competing products in Pertussis Immunisation

See all competitors

Product	Company	Stage	Hype Score
Adacel®	Sanofi	Approved	84
aP booster + TdaP booster + Licensed TdaP booster (Boostrix®)	Novartis	Phase 1	33
Boostrix + Placebo (Saline)	Novartis	Approved	85
Acellular pertussis vaccine + Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) + Licensed TdaP booster vaccine + Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)	Novartis	Phase 1	33
Tetanus Toxoid, acellular pertussis, diphtheria toxoid	Sanofi	Pre-clinical	22
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed	Sanofi	Approved	84
COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)	Sanofi	Approved	84
(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis	Sanofi	Phase 1/2	40
DT5aP-IPV-Hib 5-component Pertussis vaccine + Infanrix® -IPV+Hib	Sanofi	Phase 3	76
Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV + Hepatitis B vaccine	Sanofi	Phase 2	51
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliomyelitis Vaccine	Sanofi	Approved	84
Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®) + Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)	Sanofi	Approved	84
Pentacel® (DTaP-IPV/Hib) + Other Pertussis Vaccines	Sanofi	Pre-clinical	22
DTaP-IPV combined vaccine + DTaP vaccine	Sanofi	Phase 3	76
ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed + DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed	Sanofi	Approved	84
Tetanus and diphtheria toxoids and acellular pertussis	Sanofi	Pre-clinical	22

Other Products from Sanofi

Adacel®Approved

LACTIC ACID(ND)Approved

DupilumabApproved

glatiramer acetateApproved

INSULIN GLULISINE + INSULIN GLARGINEApproved